Immuron Limited achieved four consecutive quarters of sales growth in FY26, recording global revenue of AUD$7.7 million, a 6% increase on the prior comparative period (pcp). The Australian biopharmaceutical company attributed the performance to strong demand for its immune supplement Travelan®, particularly in Australia and the U.S., alongside a recovery in the Canadian market. The 2H FY26 sales reached AUD$3.5 million, up 7% on pcp, while 4Q FY26 sales stood at AUD$2.0 million, a 2% increase on pcp.

Regional Performance

Australian sales continued to drive growth, rising 10% on pcp to AUD$5.8 million for the full year. The company cited increased awareness from digital and social media marketing, same-store growth, and expansion into new stores within banner groups secured in FY25 as key factors. Increased travel to South East Asia also contributed to the positive trend. In the U.S., sales increased 7% on pcp in AUD terms to AUD$1.8 million, or 13% on pcp in USD terms to USD$1.2 million, supported by improved Amazon presence and targeted social media initiatives.

Canadian Recovery

Canadian sales, which totaled AUD$0.2 million for the year (down 55% on pcp), showed a sharp rebound in the second half. Following a Q1 FY25 pipeline fill into over a thousand retail doors, Q4 FY26 sales surged 376% on pcp. The company reported that consumer promotions and educational programs successfully built brand awareness, resulting in significant sequential growth throughout the year.

Financial Highlights

The following table details the sales performance across key regions for FY26, 2H FY26, and 4Q FY26:

The company noted that new Travelan packaging and creative launched in Q4 FY26 are expected to positively impact future sales. The strengthening of the Australian dollar against the U.S. dollar partially offset the reported growth in U.S. dollar terms.

Immuron Limited has engaged Pullan Consulting to assist in securing a strategic partnership for IMM-529, a product designed to prevent or treat Clostridioides difficile infection (CDI). The company aims to find a partner to support clinical development through regulatory approval and commercialization. An opportunity assessment indicates that if efficacious, IMM-529 is projected to generate a base case yearly revenue of US$400M.

Pullan Consulting is a life sciences advisory firm specializing in guiding biotechnology and pharmaceutical companies through the partnering process. The firm has executed between five and twelve partnering transactions annually over the past 20 years. Its expertise is expected to support Immuron in maximizing the value of IMM-529 while advancing the program toward commercialization.

Immuron has secured U.S. Food and Drug administration (FDA) approval for its Investigational New Drug (IND) application (IND 32095). The company has completed an Investigational Brochure and clinical protocol, secured a principal investigator and three Australian sites, and manufactured drug product for supply. The trial is eligible for Australia’s Clinical Trial Notification (CTN) scheme, a fast-track method for initiating trials.

IMM-529 has a validated biological target. FDA-approved monoclonal antibody Bezlotoxumab was developed as a first-in-class therapy designed to prevent recurrence of CDI by neutralizing toxin B. IMM-529’s polyclonal antibodies offer multivalent defense compared with monoclonal single-epitope antibodies. IMM-529 also has an advantage over current standard of care antibiotic treatments that disrupt microbiota. IMM-529 decolonizes the gut facilitating clearance of the pathogen, recovery of the microbiome and prevention of recurrent infection.

The Phase 2 clinical trial protocol is for a randomized, double blind, placebo-controlled study of IMM-529 with Standard of Care (SOC) for the treatment of CDI. Up to 60 subjects will be enrolled, with randomization in a 2:1 ratio. The primary objective is to evaluate safety and tolerability, while efficacy will be assessed by measuring mortality rate, disease symptoms, and recurrence rate.

Pre-clinical models have shown promising results, including prevention of primary disease (80%), protection of disease recurrence (67%), and treatment of primary disease (78.6%). The company is seeking partners under a licensing model where the licensee typically funds development, registration, and commercialization costs.